Nordic Life Science 1
TOP STORIES BUSINESS Monica Wallter, CEO, LIDDS I
N V E STMENT Turku produces cytostatic cancer drugs, which are sold globally. Through the investments, the cancer drug department at the plant will be upgraded by adding a blister packaging line to the production chain, alongside the existing bottle lines. The production volumes in the cream and ointment department have also increased steadily over the years. Now Orion is investing in expanding and modernising the facilities. The department manufactures basic creams and medical creams, with especially veterinary ointments and liquid medicines made for international markets. “Over the past five years, Orion has invested around EUR 160 million in its production plants in Finland,” says Liisa Hurme, Senior Vice President, Global Operations, Orion. Stockholm’s main market can contribute to increased interest from a broader investor base, while at the same time increase the visibility and exposure of LIDDS, in Sweden and globally,” says Monica Wallter, CEO, LIDDS. LIDDS is in an expansion phase with several projects in clinical and preclinical phases, including Phase III Liproca Depot out-licensing, the Phase I NanoZoliddocetaxel study, and a preclinical program in immuno-oncology. “It is clear that our shareholder base has developed significantly in recent years, both in terms of numbers of shareholders and that we now have larger and longer-term institutional and private investors,” says Jan Törnell, Chairman of the Board, LIDDS. Liisa Hurme, Senior VP, Global Operations, Orion 10 NORDICLIFESCIENCE.ORG